AC Immune SA (NASDAQ:ACIU - Get Free Report)'s stock price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $3.00 and traded as low as $2.56. AC Immune shares last traded at $2.64, with a volume of 224,004 shares traded.
Analysts Set New Price Targets
ACIU has been the subject of several research reports. StockNews.com downgraded shares of AC Immune from a "buy" rating to a "hold" rating in a research note on Tuesday, October 1st. HC Wainwright reissued a "buy" rating and issued a $16.00 price objective on shares of AC Immune in a report on Friday, November 15th.
Check Out Our Latest Stock Analysis on AC Immune
AC Immune Stock Up 2.3 %
The company has a market cap of $267.24 million, a PE ratio of -5.88 and a beta of 1.29. The business has a 50-day simple moving average of $3.00 and a 200-day simple moving average of $3.26.
Institutional Investors Weigh In On AC Immune
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its stake in AC Immune by 6.4% in the 3rd quarter. Geode Capital Management LLC now owns 58,296 shares of the company's stock valued at $220,000 after buying an additional 3,499 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of AC Immune by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company's stock worth $72,000 after purchasing an additional 7,400 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in AC Immune in the 2nd quarter valued at $218,000. Finally, Renaissance Technologies LLC lifted its holdings in AC Immune by 26.4% in the 2nd quarter. Renaissance Technologies LLC now owns 652,079 shares of the company's stock valued at $2,602,000 after purchasing an additional 136,300 shares in the last quarter. Hedge funds and other institutional investors own 51.36% of the company's stock.
AC Immune Company Profile
(
Get Free Report)
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Featured Articles
Before you consider AC Immune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AC Immune wasn't on the list.
While AC Immune currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
